Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Weber to Become CEO of Takeda in April
March 4, 2015
- Announcement: 12th Annual BIO Asia International Conference to Be Held on March 24, 25
March 4, 2015
- Japan Units of Abbott, Mylan to Run Separate Operations for Now
March 4, 2015
- Almac Aims to Expand Japan Business
March 4, 2015
- Santen Files Sirolimus for Noninfectious Uveitis in Europe
March 4, 2015
- Chugai, Athersys Join Hands for Cell Therapy Treatment
March 4, 2015
- Taiho Files Lonsurf for EU Approval
March 4, 2015
- Torii to Market 2 Anti-HIV Drugs Containing Tenofovir Alafenamide in Japan
March 3, 2015
- Switch OTC Drug Market Grows to 162 Billion Yen in 2014: Fuji Keizai
March 3, 2015
- Novartis Offers Apologies over Biz Suspension, Vows to Prevent Recurrence
March 2, 2015
- Jinarc Approved for Autosomal Dominant Polycystic Kidney Disease in Canada: Otsuka
March 2, 2015
- Eli Lilly Aims to Lead Japan Diabetes Market by 2020
March 2, 2015
- MTPC Eyes Total Sales of Over 100 Billion Yen for Remicade, Simponi
February 27, 2015
- Takeda Launches Takecab, to Copromote with Otsuka
February 27, 2015
- Medicago Signs Up with US Govt Agency for Development of Production Process for Ebola Antibodies
February 27, 2015
- Shionogi to Reorganize in April to Beat Biz Strategy Goals for FY2020
February 26, 2015
- Avigan Shows Promise in Treatment of Ebola in Clinical Trial
February 26, 2015
- NanoCarrier Concludes Joint Research Agreement with Chugai to Develop Next-Generation Anticancer Drugs
February 26, 2015
- Eisai to File Halaven for Soft Tissue Sarcomas; PIII Study Results Show Significant Prolongation of OS
February 26, 2015
- Takeda to Acquire Turkish Firm for Up to 14.5 Billion Yen, Earn 13 Branded Generics
February 25, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…